GSK discount wins U.K. backing for Revolade; Lilly plots another $1.5B in stock buybacks;

@FiercePharma: A blow to Roche's Avastin hopes as NICE rejects it for Ovarian Cancer. Article | Follow @FiercePharma

> GlaxoSmithKline ($GSK) persuaded U.K. cost-effectiveness officials to back its Revolade blood drug by offering a discount. Report

> Eli Lilly ($LLY) directors approved a new $1.5 billion stock-buyback plan for 2013, on top of $3 billion in share repurchases over the past dozen years. Report

> Shire's ADHD drug Vyvanse won approval from U.K. gatekeepers, clearing the way for approval in 7 other countries that participated in a decentralized review of the drug under EU rules. Report

> Sun Pharmaceutical Industries snapped up the generics business of URL Pharma, a U.S. subsidiary of Takeda Phamaceuticals. Report

> Apotex and Aurobindo Pharma won FDA approval for their versions of the ViiV Healthcare HIV drug Ziagen. Report

Medical Device News

 @FierceMedDev: Quidel wins 510(k) for C. difficile molecular Dx. More | Follow @FierceMedDev

@MarkHFierce: More Dx funding--this time for Ortho Kinematics, a spine imaging Dx company--$2M Series B. Item | Follow @MarkHFierce

 @DamianFierce: Medtronic posts more good renal denervation data, but it faces mounting competition from $BSX, $STJ. Story | Follow @DamianFierce

> St. Jude Medical enrolls first patient in cardiac stent imaging guidance trial. Article

> GE licenses Alzheimer's imaging agent to Merck. Report

> Disgraced ex-Home Diagnostics head avoids jail time. News

Biotech News

 @FierceBiotech: Celgene wraps $500M deal to partner with Sutro on next-gen ADCs. Article | Follow @FierceBiotech

@JohnCFierce: Hey, Actelion is (kind of) on a roll, with positive psoriasis data on PhII drug. Handily beats placebo. Article | Follow @JohnCFierce

@RyanMFierce: Interesting how Merck is using GE's experimental imaging agent in Alzheimer's trial for MK-8931. Does this add risk? Report | Follow @RyanMFierce

> Vanda shares soar on positive PhIII data. Item

> Troubled drug developer Enzon looks for buyer as Icahn asks for chat. News

> Langer biotech adds $16M in venture cash to back next-gen cancer drugs. Story

Pharma Manufacturing News

> ICIG adds Tessenderlo plants to its portfolio. Report

> Teva puts brakes on $300M Philly warehouse. News

> FDA's counterfeit drug probe sweeps up cancer doc. Article

Biotech Research News

> Acetylon's HDAC drug fights sickle cell disease, beta thalassemia in blood cell studies. Item

> Lifting the mood: Antidepressant could double as diabetes drug. Report

> Engineered viruses rebuild heartbeat. Article

> Rejected diabetes drug wakes up cell memories in Alzheimer's. News

> Gene therapy flips switch in sickle cell disease. Story

And Finally... Why is Rudolph's nose red? Ask the BMJ. Report (sub. req.)

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.